Cortexyme

Given Cortexyme’s higher probable upside, equities research analysts clearly believe Cortexyme is more favorable than Seattle Genetics.

Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models.

Cortexyme is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.